New hope for rare skin disease: drug targets repeated flares
NCT ID NCT06013969
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study tests whether the drug spesolimab can safely and effectively treat repeated flares of generalized pustular psoriasis (GPP), a serious skin condition. About 42 adults with a history of GPP flares will receive a single infusion of spesolimab at the start of a flare, with a possible second dose one week later. Doctors will check for clear skin and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST degli Spedali Civili di Brescia
Brescia, 25123, Italy
-
Chang Gung Memorial Hospital, Linkou
Taoyuan District, 330, Taiwan
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Faculdade de Medicina do ABC
Santo André, 09060-870, Brazil
-
Farhat Hached Hospital
Sousse, 4000, Tunisia
-
HOP Saint-Louis
Paris, 75010, France
-
HOP Trousseau
Chambray-lès-Tours, 37170, France
-
Hedi Chaker Hospital, Department of Dermatology
Sfax, 1053, Tunisia
-
Hospital Kuala Lumpur
Kuala Lumpur, 50586, Malaysia
-
Hospital Pulau Pinang-Pulau Pinang-21953
Georgetown Pulau Pinang, 10990, Malaysia
-
Hospital Putrajaya
Putrajaya, 62250, Malaysia
-
Hospital Selayang
Batu Caves, 68100, Malaysia
-
Hospital Sultan Ismail
Johor Bahru, 81100, Malaysia
-
Hospital Sultanah Aminah
Johor Bahru, 80100, Malaysia
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Evangelico Mackenzie
Curitiba, 80440-220, Brazil
-
Hospital Universitario Ramon Y Cajal
Madrid, 28034, Spain
-
Klinikum der Universität München AÖR
München, 80337, Germany
-
Liverpool Hospital
Liverpool, New South Wales, 2170, Australia
-
Maharat Nakhonchiangmai Hospital
Muang Chiang Mai, 50200, Thailand
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
National University Hospital-Singapore-42005
Singapore, 119228, Singapore
-
Nelson Mandela Academic Clinical Research Unit (NeMACRU)
Mthatha, Eastern Cape, 5099, South Africa
-
Nkp Salve Institute of Medical Sciences and Lata Mangeshkar Hospital
Nagpur, 440019, India
-
Red River Research Partners, LLC
Fargo, North Dakota, 58103, United States
-
SP medical college and associated group of hospitals
Bikaner, 334003, India
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
Shanghai Tenth People's Hospital
Shanghai, 200072, China
-
Southern Medical University Dermatology Hospital
Guangzhou, 510091, China
-
Srinagarind Hospital
Khon Kaen, 40000, Thailand
-
Sunway Medical Centre
Selangor Darul Ehsan, 47500, Malaysia
-
University of California Irvine
Irvine, California, 92697, United States
-
Universitätsklinikum Frankfurt
Frankfurt am Main, 60596, Germany
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.